Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17410978 | 0.90 | SIRT6 (0.74) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL17197439 | 0.86 | ALDH1A1 (0.64) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL17197339 | 0.85 | ALDH1A1 (0.60) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL31498851 | 0.84 | ALDH1A1 (0.61) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL17411235 | 0.83 | SIRT6 (0.81) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL520015 | 0.82 | SIRT6 (1.00) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL17197284 | 0.81 | LMNA (0.54) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL30497528 | 0.81 | LMNA (0.54) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL29267646 | 0.80 | LMNA (0.76) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL31498866 | 0.80 | LMNA (0.56) | SIRT6ALDH1A1LMNAMAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| WO-2015158310-A1 | TYROSINE KINASE INHIBITOR AND USES THEREOF | 山东轩竹医药科技有限公司 | 2015-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | SIRT6 3491/4885ALDH1A1 2257/4885LMNA 4110/4885 |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | EGFR, ERBB2, ABL1 | SIRT6 3491/4885ALDH1A1 2257/4885LMNA 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.